INCB3619: ADAM inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 11625778 |
| CHEMBL ID | 434567 |
| SCHEMBL ID | 209111 |
| MeSH ID | M0501383 |
| Synonym |
|---|
| CHEMBL434567 , |
| methyl (6s,7s)-7-[(hydroxyamino)carbonyl]-6-[(4-phenyl-3,6-dihydropyridin-1(2h)-yl)carbonyl]-5-azaspiro[2.5]octane-5-carboxylate |
| (6s,7s)-methyl 7-(hydroxycarbamoyl)-6-(4-phenyl-1,2,3,6-tetrahydropyridine-1-carbonyl)-5-azaspiro[2.5]octane-5-carboxylate |
| bdbm50203527 |
| unii-q56ue7e40y |
| 5-azaspiro(2.5)octane-5-carboxylic acid, 6-((3,6-dihydro-4-phenyl-1(2h)-pyridinyl)carbonyl)-7-((hydroxyamino)carbonyl)-, methyl ester, (6s,7s)- |
| incb 3619 |
| incb-3619 |
| 791826-72-7 |
| q56ue7e40y , |
| 5-azaspiro(2.5)octane-5-carboxylic acid, 6-((3,6-dihydro-4-phenyl-1(2h)-pyridinyl)carbonyl)-7-((hydroxyamino)carbonyl)-, methyl ester, (6s,7s)- |
| SCHEMBL209111 |
| methyl (5s,6s)-5-(hydroxycarbamoyl)-6-(4-phenyl3,6-dihydro-2h-pyridine-1-carbonyl)-7-azaspiro[2.5]octane-7-carboxylate |
| incb3619 |
| gtpl8679 |
| Q27892968 |
| iai-100 |
| methyl (6s,7s)-7-(hydroxycarbamoyl)-6-(4-phenyl-3,6-dihydro-2h-pyridine-1-carbonyl)-5-azaspiro[2.5]octane-5-carboxylate |
| CS-0012124 |
| AKOS040748575 |
| HY-12636 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Disintegrin and metalloproteinase domain-containing protein 10 | Homo sapiens (human) | IC50 (µMol) | 0.0312 | 0.0081 | 1.4852 | 10.0000 | AID1235676; AID1895847; AID277511; AID344625 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Sus scrofa (pig) | IC50 (µMol) | 0.0140 | 0.0010 | 1.3365 | 8.0000 | AID1895848 |
| Interstitial collagenase | Homo sapiens (human) | IC50 (µMol) | 5.0000 | 0.0002 | 0.8502 | 10.0000 | AID277512; AID349373 |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | IC50 (µMol) | 0.0680 | 0.0001 | 0.5453 | 10.0000 | AID277510 |
| 72 kDa type IV collagenase | Homo sapiens (human) | IC50 (µMol) | 0.0370 | 0.0000 | 1.2848 | 10.0000 | AID277513; AID349374 |
| Stromelysin-1 | Homo sapiens (human) | IC50 (µMol) | 3.7800 | 0.0000 | 1.1484 | 10.0000 | AID277514; AID349375 |
| Matrilysin | Homo sapiens (human) | IC50 (µMol) | 5.0000 | 0.0014 | 2.0859 | 10.0000 | AID349378 |
| Matrix metalloproteinase-9 | Homo sapiens (human) | IC50 (µMol) | 0.3660 | 0.0000 | 0.7053 | 10.0000 | AID277515; AID349379 |
| Macrophage metalloelastase | Homo sapiens (human) | IC50 (µMol) | 0.0170 | 0.0002 | 2.7217 | 10.0000 | AID349385 |
| Matrix metalloproteinase-14 | Homo sapiens (human) | IC50 (µMol) | 0.7720 | 0.0003 | 0.7182 | 10.0000 | AID1235677; AID349381 |
| Disintegrin and metalloproteinase domain-containing protein 8 | Homo sapiens (human) | IC50 (µMol) | 1.0000 | 1.0000 | 1.0000 | 1.0000 | AID344631 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | IC50 (µMol) | 0.5070 | 0.0002 | 1.0140 | 10.0000 | AID1235688; AID349383 |
| Disintegrin and metalloproteinase domain-containing protein 9 | Homo sapiens (human) | IC50 (µMol) | 5.0000 | 0.0010 | 2.5284 | 10.0000 | AID344626 |
| Disintegrin and metalloproteinase domain-containing protein 33 | Homo sapiens (human) | IC50 (µMol) | 1.0260 | 1.0260 | 1.0260 | 1.0260 | AID344620 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (22.22%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (77.78%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||